News and Events

Clinical trial researches therapy for VEXAS syndrome

A clinical trial led by Dennis Hickstein, M.D., Senior Investigator in the Immune Deficiency Cellular Therapy Program, is researching a therapy for people with VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) syndrome.

Protein signature in the blood linked to prostate cancer lethality in men of African ancestry

African American men have an increased risk for lethal prostate cancer. CCR researchers have found that an immunity-related protein signature in the blood is more prevalent in men of African ancestry, which may help explain this devastating health disparity.

Clinical trial researches three-part immunotherapy regimen for gastric or head and neck cancer

Jason M. Redman, M.D., Assistant Research Physician in the Genitourinary Malignancies Branch, is leading a study researching a three-part immunotherapy regimen in adults with gastric or head and neck cancer.

CCR scientists to present at 2022 AACR Annual Meeting in New Orleans

The American Association for Cancer Research (AACR) Annual Meeting is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine. Several CCR scientists will present their research at the AACR Annual Meeting.

A series of images depicting computed tomography (CT) scans of prostate cancer.

Clinical trial aims to reduce hormone therapy side effects for people with prostate cancer

A team at CCR is investigating a new device to deliver hormone therapy directly into prostate cancer tumors. The approach could improve patient quality of life by reducing burdensome side effects of current hormone therapies.

New Milestones publication now available

Every year, CCR makes remarkable contributions to the understanding, detection, treatment and prevention of cancer. This issue of our annual publication, Milestones, features 14 of our top scientific advances from the past year. These discoveries include basic research to understand cancer cells, promising advances in immunotherapy for solid tumors, precision oncology for selecting the best treatment for a patient and new insights into the role of the tumor microenvironment and the microbiota in cancer treatment. Other major advances include new technology development achieved through interdisciplinary teamwork, health disparities research relating to prostate cancer and studies that led to several Food and Drug Administration approvals.

First-in-human clinical trial evaluates drug for pancreatic cancer and other solid tumors

Christine Alewine, M.D., Ph.D., a Lasker Clinical Research Scholar in the Laboratory of Molecular Biology, is leading CCR participation in a first-in-human trial to evaluate a drug for therapy of pancreatic cancer and other solid tumors. The drug aims to attack a physical barrier that helps to hide the tumor from the body’s immune system.

Steven Pavletic named Top Ten Clinical Research Achievement awardee

Steven Z. Pavletic, M.D., M.S., Senior Clinician in the Immune Deficiency Cellular Therapy Program, has been named a Top Ten Clinical Research Achievement awardee by the Clinical Research Forum for his study “A randomized phase 2 trial of pomalidomide in subjects failing prior therapy for chronic graft-versus-host disease.”

Clinical trial studies combination therapy for relapsed/refractory B-cell lymphomas

Burkitt lymphoma and diffuse large B-cell lymphoma are fast-growing cancers, and new therapies are needed for adults whose disease is not effectively treated with chemotherapy alone. Investigators at CCR are studying a combination therapy as a potential treatment for people with these aggressive cancers.

Following the fellowship experience with CCR fellow Martha Teke, M.D.

Martha Teke, M.D., is a research fellow in the Surgical Oncology and Cancer Immunotherapy Research Fellowship Program. In this Q&A, she shares her experience as a clinical fellow at CCR and what impact she hopes to leave in the world of science.

Breadcrumb